Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
ASND Stock Chart & Stats
$217.32
-$0.55(-0.40%)
At close: 4:00 PM EST
$217.32
-$0.55(-0.40%)
Day’s Range― - ―
52-Week Range$118.03 - $229.94
Previous CloseN/A
Volume129.18K
Average Volume (3M)676.48K
Market Cap
$13.28B
Enterprise Value$12.40B
Total Cash (Recent Filing)$539.09M
Total Debt (Recent Filing)$813.65M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Feb 12, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding61,151,463
10 Day Avg. Volume632,835
30 Day Avg. Volume676,484
Financial Highlights & Ratios
PEG Ratio0.86
Price to Book (P/B)-72.81
Price to Sales (P/S)21.17
P/FCF Ratio-25.02
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue19.18
Enterprise Value/Gross Profit22.10
Enterprise Value/Ebitda-93.13
Forecast
1Y Price Target
$267.92Price Target Upside23.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)4.28
Revenue Forecast (FY)$1.54B
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DifferentiationClinical data indicate the TransCon CNP plus growth hormone combination produced greater growth velocity and improved body proportionality and arm span versus monotherapy, creating a clear efficacy differentiation that could influence physician and caregiver treatment choices.
Geographic And Indication ExpansionPlanned development for hypochondroplasia and opportunity in ex‑US markets with large patient populations offer meaningful commercial expansion potential as new launches and label opportunities progress.
Safety And Tolerability ProfileSafety and tolerability findings for the combination are consistent with prior results and show no concerning bone‑related safety events, supporting confidence for longer‑term use by clinicians.
Bears Say
Competitive Threat From Oral TherapiesAn oral competitor that avoids injections could attract patients seeking convenience and present a material threat to uptake of an injectable TransCon CNP regimen.
Dosing And Formulation Adherence RiskThe combination currently requires two separate injections and the absence of a disclosed timeline for a single‑injection coformulation could hinder adherence and make it harder to protect market share from off‑label combinations.
Regulatory And Execution UncertaintyRegulatory timing uncertainty and an unexpected review extension introduce execution risk that could delay approval and negatively affect investor sentiment.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $118.03 and its highest was $229.94 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $13.28B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Feb 12, 2026 which is in 27 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Nov 12, 2025. The company reported -$1.164 earnings per share for the quarter, missing the consensus estimate of -$0.284 by -$0.88.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is -0.14.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 61,151,463 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$1.164 in its last earnings report, missing expectations of -$0.284. Following the earnings report the stock price went up 3.629%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Currently, no hedge funds are holding shares in ASND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$267.92 (23.28% Upside)
$267.92 (23.28% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 124.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.15%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ASND Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and expansion in global markets for Eurvipath and Skytrofa, regulatory approvals, and a positive operating profit. However, challenges remain with the conversion rate for insurance approvals and increased SG&A expenses due to commercial expansion. Foreign currency impacts also affected revenue growth.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$267.92
▲(23.28% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Madrigal Pharmaceuticals
―
United Therapeutics
―
BridgeBio Pharma
―
Ownership Overview
Currently, No data available
---